The American Association of Cancer research has elected Manuel Hidalgo new member of the B... 21/05/2024 Healthcare Corporate Dr. Manuel Hidalgo is working with Peaches Biotech in the development of a new treatment called opT cells, born from a... Partners - PEACHES BIOTECH S.L.
Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate... 21/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies. Partners - AptaTargets
AMSbiopharma presents a major breakthrough with the analysis of nitrosamines in active pha... 21/05/2024 Healthcare Access to innovation Nitrosamines represent a significant health risk, being potentially carcinogenic and a major concern in pharmaceutical... Partners - AMSbiopharma
#NewAseBioMember | “This partnership gives us the possibility to establish key contacts an... 20/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal. AseBio - Kirsch Pharma España
Biotechnology revolutionizes advances against obesity: enhanced understanding, more accura... 18/05/2024 Healthcare Access to innovation To address how biotechnology is enabling progress in combating obesity from various perspectives, and in celebration of... AseBio
Oryzon to provide corporate progress updates at several events in May 09/05/2024 Healthcare Financing Corporate Oryzon Genomics will attend and participate, both as speaker and guest, in different events related to biotechnology and... Partners - Oryzon Genomics
#AseBioID24 | “Being present at Investor Day gives you wings to visualize, work and promot... 08/05/2024 Healthcare Access to innovation Advanced therapies Financing Hector Olabegogeaskoetxea Narbaiza, CEO of MONDRAGON Health, Silver Sponsor of AseBio Investor Day, analyzes the biotech... AseBio
Oryzon reports financial results and corporate update for quarter ended March 31, 2024 07/05/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies Financing Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD)... Partners - Oryzon Genomics
#AseBioID24 | "These types of events are essential, considering how difficult it usually i... 06/05/2024 Healthcare Financing We analyze the challenges that biotechnology companies face in terms of financing, with David Roberto García, Chief... AseBio - Laminar Pharma
#AseBioID24 | 'The Investor Day is a reference event for the national ecosystem primarily,... 03/05/2024 Healthcare Financing We interviewed Roger Pique, General Partner at Inveready, Bronze Sponsor of the AseBio Investor Day 2024. AseBio - Inveready
